Engineering the next generation of gene editing tools to cure diseases.

At Integra Therapeutics we have combined the precision of CRISPR systems with the gene transfer efficiency of viral integrases and transposases.

Harnessing what nature has evolved to introduce large pieces of DNA into the genome, together with the precision of sequence specific DNA binding proteins, has allowed for unprecedented efficiency in programmable gene delivery. ​

Addressing the current limitations of Gene Editing

Size

Precision

Stability

Size

Precision

Stability

Stable and precise integration of full-length genes of any size will unlock the full potential of gene therapy to meet patients needs.

Founder team

Dra. Avencia Sánchez-Mejías

Co-founder, CEO

Dra. Sanchez-Mejías Senior has a strong scientific background in biomedical research, she has contributed to the understanding of different aspects of human diseases with her work in the United States, Singapore, and Spain. She is fully committed to the transferring of the technical advances in the field of gene editing generated at the Pompeu Fabra University to the industry, to fulfill patient’s expectations.

Dr. Marc Güell

Co-founder, CSO

Dr. Güell holds a strong record of original, solid, ambitious and scientifically and socially relevant research. His work includes several synthetic biology breakthroughs (high CRISPR multiplexing, radically recoded genomes, PERVs-free pigs, skin microbiome modulation, programmable gene delivery) that have produced important impact (>11,000 cit., companies developing therapies, patents licensed to leading companies). He was recently named EMBO Young Investigator (2020), highly cited researcher (2019), and received the National Research Award to the Young talent (2018).